UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D
(Amendment No. 4)
 
Under the Securities Exchange Act of 1934

Growblox Sciences, Inc.
(Name of Issuer)
 
Common Stock
(Title of Class of Securities)
 
 
399847 102
 
  (CUSIP Nubmer)  
 
Adam D. Averbach, Esq.
Lazarus Management Company LLC
3200 Cherry Creek South Drive, Suite 670
Denver, CO  80209
(303) 500-8821
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

April 27, 2015
(Date of event which requires filing of this statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because § 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g) check the following box o
 

CUSIP No. 399847 102
 
1.
 NAMES OF REPORTING PERSONS
 
 Lazarus Management Company LLC  
 
2.
 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
 (a)   o
 (b)   x
3.
 SEC USE ONLY
4.
 SOURCE OF FUNDS
 
 PF, OO
5.
 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
 
 x
6.
 CITIZENSHIP OR PLACE OF ORGANIZATION
 
 Colorado
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
7.
 SOLE VOTING POWER
 
 8,691,479
8.
 SHARED VOTING POWER
 
 0
9.
 SOLE DISPOSITIVE POWER
 
 8,691,479
10.
 SHARED DISPOSITIVE POWER
 
 0 
11.
 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
 8,691,479
12.
 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
 
 o
13.
 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
 
 22.3%
14.
 TYPE OF REPORTING PERSON
 
 IA
 
 
1

CUSIP No. 399847 102
 
1.
 NAMES OF REPORTING PERSONS
 
 Justin B. Borus 
 
2.
 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
 (a)   o
 (b)   x
3.
 SEC USE ONLY
4.
 SOURCE OF FUNDS
 
 PF, OO
5.
 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
 
 o
6.
 CITIZENSHIP OR PLACE OF ORGANIZATION
 
 United States
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
7.
 SOLE VOTING POWER
 
 8,691,479
8.
 SHARED VOTING POWER
 
 0
9.
 SOLE DISPOSITIVE POWER
 
 8,691,479
10.
 SHARED DISPOSITIVE POWER
 
 0 
11.
 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
 8,691,479
12.
 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
 
 o
13.
 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
 
 22.3%
14.
 TYPE OF REPORTING PERSON
 
 IN/HC
 
 
 
2

 
CUSIP No. 399847 102
 
1.
 NAMES OF REPORTING PERSONS
 
 Lazarus Investment Partners LLLP 
 
2.
 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
 (a)   o
 (b)   x
3.
 SEC USE ONLY
4.
 SOURCE OF FUNDS
 
 PF, OO
5.
 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
 
 o
6.
 CITIZENSHIP OR PLACE OF ORGANIZATION
 
 Delaware
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
7.
 SOLE VOTING POWER
 
 6,269,632
8.
 SHARED VOTING POWER
 
 0
9.
 SOLE DISPOSITIVE POWER
 
 6,269,632
10.
 SHARED DISPOSITIVE POWER
 
 0 
11.
 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
 6,269,632
12.
 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
 
 o
13.
 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
 
 16.5%
14.
 TYPE OF REPORTING PERSON
 
 PN 
 
 
3

CUSIP No.399847 102
 
1.
NAMES OF REPORTING PERSONS
 
 Lazarus Israel Opportunities Fund LLLP
 
2.
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
 
(a) o
(b) x
3.
SEC USE ONLY
4.
SOURCE OF FUNDS
 
 
 PF, OO
5.
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
 
o
6.
CITIZENSHIP OR PLACE OF ORGANIZATION
 
 
 Delaware
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
7.
SOLE VOTING POWER
 
 2,421,847
8.
SHARED VOTING POWER
 
 0
9.
SOLE DISPOSITIVE POWER
 
 2,421,847
10.
SHARED DISPOSITIVE POWER
 
 0
11.
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
 2,421,847
12.
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
 
o
13.
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
 
 6.8%
14.
TYPE OF REPORTING PERSON
 
 PN
 

 
4

 
Explanatory Note

This Amendment No. 4 amends and supplements the statement on Schedule 13D originally filed by Lazarus Investment Partners LLLP ("Lazarus Partners"), Lazarus Israel Opportunities Fund LLLP ("Lazarus Israel"), Lazarus Management Company LLC ("Lazarus Management") and Justin B. Borus (collectively, the "Reporting Persons") on June 9, 2014, as amended from time to time (the "Schedule 13D").  All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D.  The information set forth in response to each Item below shall be deemed to be a response to all Items where such information is relevant.

Item 3.  Source and Amount of Funds or Other Consideration.

The responses to Items 4, 5 and 6 of the Schedule 13D are incorporated herein by reference.

Item 4.  Purpose of Transaction.

Item 4 of the Schedule 13D is hereby supplemented by adding the following:

On April 27, 2015, Lazarus Partners and Lazarus Israel entered into a warrant purchase agreement with the Issuer pursuant to which the Issuer repurchased warrants to purchase 3,000,000 shares of common stock from Lazarus Partners and warrants to purchase 1,000,000 shares of common stock from Lazarus Israel, for a purchase price of $0.01 per warrant share, resulting in cash consideration of $30,000 to Lazarus Partners and $10,000 to Lazarus Israel.  The warrants had an original exercise price of $2.00 per share and would have expired in 2019.

Item 5.  Interest in Securities of the Issuer.

Item 5 of the Schedule 13D is hereby supplemented by adding the following:

Reference is made to Items 7, 9, 11 and 13 of pages 2-5 of the Schedule 13D, which items are incorporated by reference.  The securities reported on the Schedule 13D by Lazarus Partners consist of 3,269,632 shares of common stock and warrants to purchase an additional 3,000,000 shares of common stock.  The securities reported on the Schedule 13D by Lazarus Israel consist of 1,421,847 shares of common stock and warrants to purchase an additional 1,000,000 shares of common stock.  The securities reported on the Schedule 13D by Lazarus Management and Mr. Borus consists of the sums of the shares of common stock and warrants held by Lazarus Partners and Lazarus Israel.  The calculation of percentage of beneficial ownership in Item 13 of pages 2-5 was calculated using information obtained from the Issuer's Form 10-Q filed with the Securities and Exchange Commission on February 17, 2015, in which it stated that there were 34,904,926 shares of common stock outstanding as of February 14, 2015.

Item 6.  Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

The information disclosed in Item 4 above is incorporated herein by reference.

Item 7.  Material to Be Filed as Exhibits.

Exhibit A
   
Joint Filing Agreement, dated as of April 29, 2015, by and among Lazarus Investment Partners LLLP, Lazarus Israel Opportunities Fund LLLP, Lazarus Management Company LLC and Justin B. Borus.
Exhibit B
 
Warrant Purchase Agreement dated April 27, 2015
5

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated:  April 29, 2015

LAZARUS MANAGEMENT COMPANY LLC
 
By: /s/ Justin B. Borus
Name: Justin B. Borus
Title:  Managing Member 
 
LAZARUS INVESTMENT PARTNERS LLLP
 
By: Lazarus Management Company LLC
       its general partner
 
By: /s/ Justin B. Borus
Name: Justin B. Borus
Title:  Managing Member 


LAZARUS ISRAEL OPPORTUNITIES FUND LLLP
 
By: Lazarus Management Company LLC
       its general partner
 
By: /s/ Justin B. Borus
Name: Justin B. Borus
Title:  Managing Member 
 
 
/s/ Justin B. Borus
Justin B. Borus
 
 
 
6



 
 
EXHIBIT A

JOINT FILING AGREEMENT

This will confirm the agreement by and among the undersigned that the Schedule 13D filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the common stock of Growblox Sciences, Inc., a Delaware corporation, is being filed, and all amendments thereto will be filed, on behalf of each of the persons and entities named below in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

Dated:  April 29, 2015

LAZARUS MANAGEMENT COMPANY LLC
 
By: /s/ Justin B. Borus
Name: Justin B. Borus
Title:  Managing Member 
 
LAZARUS INVESTMENT PARTNERS LLLP
 
By: Lazarus Management Company LLC
       its general partner
 
By: /s/ Justin B. Borus
Name: Justin B. Borus
Title:  Managing Member 


LAZARUS ISRAEL OPPORTUNITIES FUND LLLP
 
By: Lazarus Management Company LLC
       its general partner
 
By: /s/ Justin B. Borus
Name: Justin B. Borus
Title:  Managing Member 
 
 
/s/ Justin B. Borus
Justin B. Borus


1


Exhibit B
 
 

WARRANT PURCHASE AGREEMENT
This Warrant Purchase Agreement (this "Agreement") is dated as of ­April 27, 2015 by and between Growblox Sciences, Inc., a Delaware corporation (the "Company" or "Growblox") and  Lazarus Investment Partners LLLP ("LIP") and Lazarus Israel Opportunities Fund LLLP ("LIOF" and together with LIP, the "Sellers").
RECITALS
A.    WHEREAS, Sellers are the holders of "B" warrants to purchase an aggregate of 4,000,000 shares of common stock of the Company (the "Warrants"); and
B.    WHEREAS,  the Company has offered to purchase the Warrants entitling the holders to purchase 4,000,000 shares of Growblox common stock (the "Warrant Shares"), for $0.01 for each Warrant Share issuable by upon full exercise of the Warrants and Sellers are willing to accept the Company's offer as provided herein.
NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Sellers and the Company mutually agree as follows:
ARTICLE I
SALE AND PURCHASE
1.1            Transfer of Warrants.  Contemporaneously with the execution of this Agreement, LIP will sell, transfer and deliver to the Company the Warrants to purchase 3,000,000 Warrant Shares and LIOF will sell, transfer and deliver to the Company the Warrants to purchase 1,000,000 Warrant Shares, in each case, duly endorsed for transfer to the Company with the assignment form to the Company duly executed.
 
1.2            Payment to Sellers.  Contemporaneously with the execution of this Agreement, the Company will pay to LIP, by wire transfer of immediately available funds to a bank account designated by LIP, a purchase price of $30,000.00, and pay to LIOF, by wire transfer of immediately available funds to a bank account designated by LIOF, a purchase price of $10,000.00; such payments aggregating $40,000.00, referred to herein as the "Purchase Price."
 
1.3            Closing.  The closing of the sale and purchase of the Warrants will take place by mail, overnight delivery, email, fax and/or wire transfer in accordance with arrangements satisfactory to the Company and the Sellers.
ARTICLE II
MISCELLANEOUS
2.1             Entire Agreement. This Agreement contains the entire understanding of the parties with respect to the subject matter hereof and supersedes all prior agreements, understandings, discussions and representations, oral or written, with respect to such matters, which the parties acknowledge have been merged into this Agreement.
 
2.2            Duly Authorized; No Conflict.  All necessary corporate action to duly approve the execution, delivery, and performance of this Agreement and the consummation of the transactions contemplated hereby has been taken by the Company.  This Agreement constitutes the valid and binding obligations of the Company enforceable in accordance with its terms.  The execution, delivery, and performance of this Agreement by the Company does not conflict with, or result in the termination or breach of any term, condition, or provision of, or constitute a default under the certificate of incorporation or bylaws of the Company, or any contract, lease, agreement, or other instrument or condition to which the Company is a party or is bound and will not violate any law, regulation, or judgment to which the Company is subject.
 
 
1

2.3            Successors and Assigns. The provisions of this Agreement shall inure to the benefit of and be binding upon the parties and their successors and permitted assigns.
 
2.4            No Third-Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other person or entity.
 
2.5            Execution. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission, or by e-mail delivery of a ".pdf" format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or ".pdf" signature page were an original thereof.
 
2.6            Severability. If any provision of this Agreement is held to be invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Agreement shall not in any way be affected or impaired thereby and the parties will attempt to agree upon a valid and enforceable provision that is a reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Agreement.
 
********************************
Balance of page intentionally left blank – signature page follows
 
 

 
2

IN WITNESS WHEREOF, the parties hereto have caused this Warrant Purchase Agreement to be duly executed as of the date first indicated above.

LAZARUS INVESTMENT PARTNERS LLLP

By:   Lazarus Management Company LLC,
         Its General Partner`

By:  /s/  Justin B. Borus
Name:  Justin B. Borus
Title:  Manager

LAZARUS ISRAEL OPPORTUNITIES FUND LLLP
`
By:    Lazarus Management Company LLC,
          Its General Partner`

By:  /s/  Justin B. Borus
Name:  Justin B. Borus
Title:  Manager

GROWBLOX SCIENCES, INC.


By:/s/ Craig Ellins
Name:
Title:  Craig Ellins, CEO

3
GB Sciences (PK) (USOTC:GBLX)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more GB Sciences (PK) Charts.
GB Sciences (PK) (USOTC:GBLX)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more GB Sciences (PK) Charts.